Inclusion Criteria:

          -  Biopsy/pathology-proven clear cell renal cell carcinoma (CCRCC) with metastases

          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status =< 1

          -  Hemoglobin >= 10 gm/dL

          -  Absolute neutrophil count (ANC) >= 1.5 x 10^9/L

          -  Platelets >= 100 x 10^9/L

          -  Total bilirubin =< upper limit of normal (ULN)

          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< ULN

          -  International normalization ratio (INR) and activated partial thromboplastin time
             (aPTT) < 1.2 x ULN

          -  Serum creatinine < 1.5 mg/dL or if serum creatinine > 1.5 mg/dL then calculate
             creatinine clearance (CrCL) > 30 mL/min

          -  Urine protein to creatinine ratio =< 1 (if urine protein creatinine ratio is > 1, then
             a 24-hour urine total protein must be assessed; subjects will be ineligible if the
             24-hour urine protein is found to be > 1 gm)

          -  Normal cardiac ejection fraction (> 50%) by multi gated acquisition scan (MUGA) or
             echocardiogram

          -  Have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
             criteria present

          -  Ability to swallow and retain oral medication

          -  Subjects of child-bearing potential must agree to use adequate contraceptive methods
             (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry
             and for the duration of study participation; should a woman become pregnant or suspect
             she is pregnant while she or her partner is participating in this study, she should
             inform her treating physician immediately

          -  Subject or legal representative must understand the investigational nature of this
             study and sign an Independent Ethics Committee/Institutional Review Board approved
             written informed consent form prior to receiving any study related procedure

        Exclusion Criteria:

          -  Subjects with known brain metastases should be excluded from this clinical trial

          -  Prior VEGF targeted therapies for renal cell carcinoma (RCC) including adjuvant or
             neoadjuvant treatments; in phase 1 only, one prior therapy with high dose IL-2 or
             anti-programmed cell death (PD)-1 compound alone or in combination with cytotoxic
             T-lymphocyte-associated protein 4 (CTLA-4) targeting drug is allowed on the trial

          -  Subjects diagnosed with another cancer in the past 3 years; excluding basal cell
             carcinoma or squamous cell carcinoma, of skin which were completely cured by resection

          -  Concurrent use of another anti-cancer drug including an investigational anti-cancer
             agent

          -  Major surgery within 28 days prior to treatment or major surgery planned during the
             next 6 months

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic or psychiatric illness/social situations that would limit
             compliance with study requirements

          -  History of any of the following cardio-vascular condition:

               -  Myocardial infarction (MI)

               -  Unstable angina

               -  Coronary artery bypass grafting (CABG)-unless patient had a negative stress test
                  within 6 months of screening

               -  Coronary angioplasty or stenting

               -  Symptomatic peripheral arterial disease (PAD)

               -  History of symptomatic chronic congestive heart failure (CHF)

               -  History of cerebrovascular accidents including transient ischemic attacks (TIA)

               -  Corrected QT interval (QTc) > 480 msec

               -  Uncontrolled hypertension (systolic blood pressure [BP] > 150 mm Hg or diastolic
                  BP of > 90 mm Hg); if the screening BP is elevated, adjustments in
                  anti-hypertensives are permitted and a re-screening will be permitted for BP
                  assessment with three consecutive values obtained 2 minutes apart; the 3 values
                  have to be below 150/90 mm Hg for eligibility and can only be obtained after 2
                  days of the last change in anti-hypertensive medication; use of clonidine is not
                  permissible for adjusting the BP during this period

          -  History of deep vein thrombosis (DVT) or pulmonary embolism (PE) in the past 6 months

          -  Subjects should not have packed red blood cells (PRBC) or platelet transfusion within
             14 days of the screening

          -  Evidence of active bleeding or bleeding disorder

          -  Subjects currently on anti-coagulation therapy are not eligible

          -  Unable to discontinue the use of prohibited medications

          -  Pregnant or nursing female subjects

          -  Unwilling or unable to follow protocol requirements

          -  Any condition which in the investigator's opinion deems the subject an unsuitable
             candidate to receive study drug

          -  Received an investigational agent within 30 days prior to enrollment